Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: A population based chart review

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  El Shayeb, Mohamed ^a   Scarfe, Andrew ^a,b   Yasui, Yutaka ^a   Winget, Marcy ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c ALBERTA HEALTH SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANADA; CANCER STAGING; COLON TUMOR; FEMALE; HEALTH CARE PLANNING; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PHYSICIAN; RETROSPECTIVE STUDY; STATISTICS; TREATMENT REFUSAL;

AGED; ALBERTA; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; HEALTH PLANNING GUIDELINES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHYSICIANS; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; TREATMENT REFUSAL;

EID: 84861876871     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-269     Document Type: Article

References (27)

1. Adjuvant therapy for patients with colon and rectal cancer. NIH consensus conference, JAMA 1990 264 1444 1450 2202842
2. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The north central cancer treatment group and the Mayo Clinic. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, J Clin Oncol 1989 7 1447 1456 2778478 (Pubitemid 19245114)
3. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA, N Engl J Med 1990 322 352 358 10.1056/NEJM199002083220602 2300087 (Pubitemid 20042739)
4. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Windle R, Bell PR, Shaw D, Br J Surg 1987 74 569 572 10.1002/bjs.1800740707 3304518 (Pubitemid 17102492)
5. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, O'Connor LC, West DW, Allen ME, Wolf RE, Wright WE, J Clin Oncol 2003 21 1293 1300 10.1200/JCO.2003.06.178 12663717 (Pubitemid 46606406)
6. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. Cree M, Tonita J, Turner D, Nugent Z, Alvi R, Barss R, King C, Winget M, Clin Colorectal Cancer 2009 8 141 145 10.3816/CCC.2009.n.023 19632928
7. Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. Jessup JM, Stewart A, Greene FL, Minsky BD, JAMA 2005 294 2703 2711 10.1001/jama.294.21.2703 16333005 (Pubitemid 41770099)
8. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF, J Clin Oncol 2002 20 1192 1202 10.1200/JCO.20.5.1192 11870160 (Pubitemid 34177424)
9. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. Schrag D, Cramer LD, Bach PB, Begg CB, J Natl Cancer Inst 2001 93 850 857 10.1093/jnci/93.11.850 11390534 (Pubitemid 32590779)
10. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: A population-based study. Sundararajan V, Grann VR, Jacobson JS, Ahsan H, Neugut AI, Cancer J 2001 7 213 218 11419029
11. Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. Winget M, Hossain S, Yasui Y, Scarfe A, Cancer 2010 116 4849 4856 10.1002/cncr.25250 20578180
12. Alberta Provincial Gastrointestinal Tumour Team, Early Stage Colon Cancer-Clinical Practice Guideline GI-004 Alberta Health Services, Alberta 2008
13. Certification for population-based cancer registries. Tucker TC, Howe HL, Weir HK, J Reg Mgmt 1999 26 24 27
14. Greene FL, Page DL, Fleming ID, Frederick L, Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, AJCC cancer staging manual Springer, New York 6 2002
15. Across-province standardization and comparative analysis of time-to-care intervals for cancer. Winget M, Turner D, Tonita J, King C, Nugent Z, Alvi R, Barss R, BMC Cancer 2007 7 186 10.1186/1471-2407-7-186 17916257 (Pubitemid 350162828)
16. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Deyo RA, Cherkin DC, Ciol MA, J Clin Epidemiol 1992 45 613 619 10.1016/0895-4356(92)90133-8 1607900
17. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA, Med Care 2005 43 1130 1139 10.1097/01.mlr.0000182534.19832.83 16224307 (Pubitemid 41587600)
18. Adjuvant chemotherapy for stage III colon cancer: Do physicians agree about the importance of patient age and comorbidity? Keating NL, Landrum MB, Klabunde CN, Fletcher RH, Rogers SO, Doucette WR, Tisnado D, Clauser S, Kahn KL, J Clin Oncol 2008 26 2532 2537 10.1200/JCO.2007.15.9434 18487570
19. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. Krzyzanowska MK, Regan MM, Powell M, Earle CC, Weeks JC, J Am Coll Surg 2009 208 202 209 10.1016/j.jamcollsurg.2008.10.016 19228531
20. Adjuvant chemotherapy among medicaid-enrolled patients diagnosed with nonmetastatic colon cancer. Foley KL, Tooze JA, Klepin HD, Song EY, Geiger AM, Am J Clin Oncol 2011 34 120 124 21499198
21. Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: a French population-based study. Quipourt V, Jooste V, Cottet V, Faivre J, Bouvier AM, J Am Geriatr Soc 2011 59 694 698 10.1111/j.1532-5415.2011.03334.x 21438864
22. Patient age and cancer treatment decisions. patient and physician views. Kutner JS, Vu KO, Prindiville SA, Byers TE, Cancer Pract 2000 8 114 119 10.1046/j.1523-5394.2000.83004.x 11898135 (Pubitemid 30233046)
23. Cancer treatment and age: Patient perspectives. Newcomb PA, Carbone PP, J Natl Cancer Inst 1993 85 1580 1584 10.1093/jnci/85.19.1580 8411231 (Pubitemid 23304686)
24. Relationship between cancer patients' predictions of prognosis and their treatment preferences. Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, Harrell FE, Kussin P, Dawson NV, Connors AF, Lynn J, Phillips RS, JAMA 1998 279 1709 1714 10.1001/jama.279.21.1709 9624023 (Pubitemid 28247301)
25. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Gross CP, McAvay GJ, Guo Z, Tinetti ME, Cancer 2007 109 2410 2419 10.1002/cncr.22726 17510973 (Pubitemid 46906459)
26. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Lima IS, Yasui Y, Scarfe A, Winget M, Cancer 2011 117 3833 3840 10.1002/cncr.25954 21319156
27. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, Neugut AI, Cancer 2006 107 2581 2588 10.1002/cncr.22316 17078055 (Pubitemid 44845611)